LEAP2: Next game-changer of pharmacotherapy for overweight and obesity?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35492250.
- Also identified by DOI 10.1016/j.xcrm.2022.100612 and PMC identifier 9044093.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The world is seeking effective and safe weight-lowering drugs for centuries. LEAP2, acting on ghrelin and growth hormone secretagogue receptor, according to a study by Hageman et al.<sup>1</sup> in this issue of <i>Cell Reports Medicine</i>, found its way toward the next target of pharmacotherapy for obesity and related diseases.
Medical subject headings
- Obesity
- Overweight